415 Capital is a Munich-based medtech venture firm backing clinical-stage companies across Europe, the US and Israel, with a focus on cardiovascular and neurovascular disease. Its partners have funded 50+ medtech companies with 25+ realized exits, including CoreValve (Medtronic) and CardiAQ (Edwards).